Compare · IMNN vs NVS
IMNN vs NVS
Side-by-side comparison of Imunon Inc. (IMNN) and Novartis AG (NVS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IMNN and NVS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVS is the larger of the two at $280.65B, about 36696.7x IMNN ($7.6M).
- Over the past year, IMNN is down 86.9% and NVS is up 25.1% - NVS leads by 112.0 points.
- IMNN has been more active in the news (6 items in the past 4 weeks vs 1 for NVS).
- NVS has more recent analyst coverage (25 ratings vs 0 for IMNN).
- Company
- Imunon Inc.
- Novartis AG
- Price
- $1.83-8.04%
- $147.06-2.50%
- Market cap
- $7.6M
- $280.65B
- 1M return
- -21.46%
- -2.24%
- 1Y return
- -86.88%
- +25.10%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 6
- 1
- Recent ratings
- 0
- 25
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Latest IMNN
- SEC Form S-8 filed by Imunon Inc.
- SEC Form 8-K filed by Imunon Inc.
- Executive Chairman of Board Tardugno Michael H was granted 4,089 shares, increasing direct ownership by 47% to 12,838 units (SEC Form 4)
- President and CEO Lindborg Stacy was granted 1,593 shares, increasing direct ownership by 44% to 5,235 units (SEC Form 4)
- Imunon Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
- IMUNON Announces Up to $10 Million Cash Financing
- Executive Chairman of Board Tardugno Michael H was granted 3,484 shares, increasing direct ownership by 66% to 8,749 units (SEC Form 4)
- Director Pellizzari Christine A was granted 5,557 shares, increasing direct ownership by 215% to 8,142 units (SEC Form 4)
- Director Dentzer James E was granted 11,148 shares, increasing direct ownership by 292% to 14,963 units (SEC Form 4)
- Director Braun Donald P was granted 5,011 shares, increasing direct ownership by 116% to 9,319 units (SEC Form 4)
Latest NVS
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- Novartis AG upgraded by Argus with a new price target
- Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
- SEC Form S-8 filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form IRANNOTICE filed by Novartis AG
- SEC Form 20-F filed by Novartis AG